KalVista Pharmaceuticals Surges on Acquisition Announcement by Chiesi Group
KalVista Pharmaceuticals (KALV) surged 38.62% following an announcement that Italy’s Chiesi Group will acquire the company for $27 per share in cash. The stock’s sharp rise was driven by the acquisition news, though investors are monitoring risks related to deal closing and regulatory approvals. The broader market saw mixed performance, with the S&P 500 slightly down and the Nasdaq Composite slightly up.
Tickers: $KALV
Topics: acquisition biotechnology pharmaceuticals rare diseases stock price movement